The Modifier-25 same-day exams during anti-VEGF therapy for neovascular age-related macular degeneration reduced treatment and travel costs at the patient and population levels, according to an expert at the virtual American Society of Retina Specialists meeting.
“Modifier-25 allows for the billing of an exam and an injection in the same day in some circumstances, but it is currently under scrutiny by payers,” H. Alexander Leder, MD, fellow of the American Academy of Ophthalmology, said during his presentation. “The purpose of this study was to evaluate the cost-benefit of
Uncategorized